Patients with untreated, advanced biliary tract cancer are needed for a study to research the combination of chemotherapy and 2 investigational drugs

UVA Tracking #
HSR210173
Principal Investigator
Tri M Le
Contact
Sallie Mannen
Contact Email
Contact Phone
434.297.5724
Official Trial Title
A phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have biliary tract cancer. The purpose of this study to evaluate 2 investigational drugs, atezolizumab and bevacizumab, in combination with chemotherapy drugs (cisplatin and gemcitabine) vs. 1 investigational drug, atezolizumab, in combination with the chemotherapy drugs in patients with biliary tract cancer. The safety and effects of the investigational and chemotherapy drugs will be evaluated for this study.

Participation includes a screening visit, drug treatment, and longer follow-up visits via a clinic visit or a phone call to keep track of how you are doing. You may receive drug as long as it continues to treat your disease. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04677504

Compensation

You will receive up to $50 per study visit; Reimbursement: You will receive up to $175 for hotel stays per night.